Status:
UNKNOWN
Evaluation of Fapi-pet in Prostate Cancer.
Lead Sponsor:
Helsinki University Central Hospital
Collaborating Sponsors:
University of Helsinki
Conditions:
Prostate Cancer
Eligibility:
MALE
18-100 years
Phase:
NA
Brief Summary
The investigators explore the biodistribution of FAPI-PET expression in primary high-risk prostate cancer in men undergoing RALP and eLND and in men with metastatic PCa about to start next generation ...
Detailed Description
This is an exploratory cohort study comprised of men with clinically localized or locally advanced high-risk prostate cancer (GG 3-5, cT2-cT3, Nx, M0) managed by RALP and eLND and men with metastatic ...
Eligibility Criteria
Inclusion
- Men scheduled for radical prostatectomy
- Age over 18 years
- GG 3-5, cT2-cT3, Nx, M0 prostate cancer
- no contraindication to PSMA - or FAPI-PET
- willing to undergo study related procedures (imaging and laboratory tests) Men scheduled for novel antiandrogen
- Age over 18 years
- GG2-5, cT2-4, N0-1, M1
- hormone sensitive or castration resistant prostate cancer
Exclusion
- Not willing or capable to undergo study related procedures
Key Trial Info
Start Date :
March 10 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 15 2022
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT05192694
Start Date
March 10 2022
End Date
December 15 2022
Last Update
March 11 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Helsinki University Hospital
Helsinki, Uusimaa, Finland, 00029